Clinical Pharmacy Lab

Publications

Jeong J, Heo KN, Lee S, Ah YM, Min S, Han JM†, Lee JY. Exploring bleeding in oral anticoagulant users: assessing incidence by indications and risk factors in the entire nationwide cohort. Front Pharmacol. 2024;15"1399955. (†co-corresponding author)

Han JM, Heo KN, Kim AJ, Lee AY, Min S, Ah YM, Lee JY. Medication-related incidents in acute care hospitals among different age groups: an analysis of national patient safety report data. Pharmacoepidemiol Drug Saf. 2024;33(6):e5819.

Kim W, Oh SJ, Kim HJ, Kim JH, Gil Y, Ku YS, Kim JH, Kim HA, Jung JY, Choi IA, Kim JH, Kim J, Han JM, Lee KE. Development of a risk prediction model for adverse skin events associated with TNF-α inhibitors in rheumatoid arthritis patients. J Clin Med. 2024;13(14):4050.

Choi HJ, Jeong YJ, Na YH, Min KM, Han JM†, Hoe HS, Lim KH. Developing theragnostics for Alzheimer's disease: Insights from cancer treatment. Int J Biol Macromol. 2024;269:131925. (†co-corresponding author)

Kim W, Lee GW, Rhee N, Min KH, Kim JH, Gil JY, Kim SY, Han JM, Lee KE. Risk factors for hyperglycemia in COVID‐19 patients treated with remdesivir. Clin Transl Sci. 2024;17(1):e13684.

Kim JY, Han JM*, Yun B, Yee J, Gwak HS. Machine learning‑based prediction of risk factors for abnormal glycemic control in diabetic cancer patients receiving nutrition support: a case-control study. Hormones (Athens). 2023;22(4):637-645. (*co-first author)

Han JM, Jang EJ, Yee J, Song T, Kim D. Park J, Gwak HS. Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban. Sci Rep. 2023;13(1):15967. 

Lee M, Han JM*, Lee J, Oh JY, K JS, Gwak HS, KH Choi. Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States. Front Pharmacol. 2023;14:1205624. (*co-first author)

Noh Y, Heo KN, Kim DA, Han JM, Lee JY, Ah YM. Risk factors for emergency department presentations after the initiation of opioid analgesics in non-cancer patients in Korea: A nationwide study. Medicina (Kaunas). 2023;59(3):519.

Han JM, Koh Y, Kim SH, Suh SY, Cho YS, Lee JH, Yu SJ, Yoon JH, Gwak HS. Evaluation of low-molecular-weight heparin for treatment of portal vein thrombosis in liver cirrhosis patients. Medicina (Kaunas). 2023;59(2):292.

Han JH, Heo KN, Han JM, Lee MS, Kim SJ, Min S, Ah YM, Lee JY. Analysis of medication errors reported by community pharmacists in the Republic of Korea: a cross-sectional study. Medicina (Kaunas). 2023;59(1):151.

Kim JY, Yee J, Yoon HY, Han JM†, Gwak HS. Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(9):3977-3989. (†co-corresponding author)

Han JM, Yee J, Cho S, Kim MK, Moon JY, Jung D, Kim JS, Gwak HS. A risk scoring system utilizing machine learning methods for hepatotoxicity prediction one year after the initiation of tyrosine kinase inhibitors. Front Oncol. 2022;12:790343.

Han JM, Choi KH, Lee HH, Gwak HS. Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis. Anticancer drugs. 2022;33(1):75-79.

Min KH, Kang SO, Oh SJ, Han JM, Lee KE. Association between gout and dementia in the elderly: a nationwide population-based cohort study. Am J Geriatr Psychiatry. 2021;29(12):1177-1185.

Kim K, Yee J, Chung JE, Kim HJ, Han JM, Kim JH, Lee KE, Gwak HS. Smartphone addiction and anxiety in adolescents: a cross-sectional study. Am J Health Behav. 2021;45(5):895-901.

Yoo HJ, Han JM*, Kim K, Song G, Yee J, Chung JE, Lee JE, Gwak HS. Association between attention deficit hyperactivity disorder and aggression subscales in adolescents. Brain behav. 2021;e02030. (*co-first author)

Shim SY, Yoon HY, Yee J, Han JM†, Gwak HS. Association between ABCA1 gene polymorphisms and plasma lipid concentration: a systematic review and meta-analysis. J Pers Med. 2021;11(9):883. (†co-corresponding author)

Kim JS, Han JM*, Cho YS, Choi KH, Gwak HS. Machine learning approaches to predict hepatotoxicity risk in patients receiving nilotinib. Molecules. 2021;26(11):3300. (*co-first author)

Cho YA, Han JM*, Kang SY, Kim DC, Youn YJ, Choi KH, Gwak HS. Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors. J Immunother. 2021;44(1):16-21. (*co-first author)

Yee J, Kim W, Han JM, Yoon HY, Lee N, Lee KE, Gwak HS. Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Sci Rep. 2020;10(1):18126.

Yoon HY, Ahn MH, Yee J, Lee N, Han JM†, Gwak HS. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2020;76(8):1053-1058. (†co-corresponding author)

Han JM, Han HW, Yee J, Kim MK, Moon JY, Cho S, Jung D, Cho YS, Seo I, Kim JY, Gwak HS. Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. Eur J Clin Pharmacol. 2020;76(8):1183-1191.

Kim K, Yee J, Kim JH, Chung JE, Lee KE, Song G, Han JM, Gwak HS. Health behaviors associated with aggression in Korean adolescents: data from 2 cross-sectional studies. Am J Health Behav. 2020;44(2):271-282.

Han JM, Yee J, Chung JE, Lee KE, Park K, Gwak HS. Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects. Mol Genet Genomic Med. 2020;8(5):1201.

Yee J, Kim SM, Han JM, Lee N, Yoon HY, Gwak HS. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep. 2020;10(1):3658.

Han JM, Yee J, Cho YS, Gwak HS. Factors influencing imatinib-induced hepatotoxicity. Cancer Res Treat. 2020;52(1):181-188.

Lee N, Park SM, Yee J, Yoon HY, Han JM†, Gwak HS. Association between glutathione-S-transferase gene polymorphisms and response to tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia: a meta-analysis. Target Oncol 2020;15(1):47-54. (†co-corresponding author)

Moon JY, Lee Y, Han JM, Lee MH, Yee J, Song MK, Kim YJ, Gwak HS. Effects of pharmacist intervention on reducing prescribing errors of investigational drugs in oncology clinical trials. J Oncol Pharm Pract. 2020;26(1):29-35.

Moon JY, Han JM*, Seo I, Gwak HS. Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast Cancer Res Treat. 2019;178(1):239-244. (*co-first author)

Kim MK, Yee J, Cho YS, Jang HW, Han JM, Gwak HS. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow up study. BMC Cancer. 2018;18(1):988.

Jung DS, Han JM*, Yee J, Kim JY, Gwak HS. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol. 2018;35(12);154. (*co-first author)

Han JM*, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, Lee JY. Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38:1124-1132.